Core Insights - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. has recently obtained the Medical Device Registration Certificate for its blood dialysis dry powder from the National Medical Products Administration, valid from November 5, 2025, to November 4, 2030 [2] - This marks the first successful registration of such a product by a company in the northwest provinces of China, indicating the company's entry into the medical device sector while continuing its focus on traditional Chinese medicine [2] - The registration is expected to enhance the company's product portfolio, create new profit growth points, and improve its overall competitiveness [2] Company Developments - The blood dialysis dry powder is widely used in clinical settings for treating acute and chronic renal failure, with the specific ion concentration model registered being "Potassium 2.0, Calcium 1.5" [2] - The product is available in various packaging options, catering to the needs of most patients and dialysis centers [2] - The company is also advancing its production line construction and production licensing for related products, including blood dialysis concentrated solutions, aiming for high-quality development [3] Industry Context - According to the Chinese Medical Association of Nephrology, the total number of dialysis patients in mainland China is projected to reach 1.183 million in 2024, with blood dialysis patients accounting for 1.027 million and new patients numbering 220,300 [3] - This indicates a rapid increase in the incidence of end-stage renal disease and the growing prevalence of dialysis treatment in the region [3]
陇神戎发血液透析干粉获医疗器械注册证 进一步拓宽产业布局